Logo image of SCLX

SCILEX HOLDING CO (SCLX) Stock Fundamental Analysis

NASDAQ:SCLX - Nasdaq - US80880W1062 - Common Stock - Currency: USD

0.3298  -0.01 (-1.7%)

After market: 0.3386 +0.01 (+2.67%)

Fundamental Rating

1

Overall SCLX gets a fundamental rating of 1 out of 10. We evaluated SCLX against 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of SCLX have multiple concerns. SCLX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SCLX had negative earnings in the past year.
In the past year SCLX has reported a negative cash flow from operations.
SCLX Yearly Net Income VS EBIT VS OCF VS FCFSCLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -164.82%, SCLX is doing worse than 87.57% of the companies in the same industry.
Industry RankSector Rank
ROA -164.82%
ROE N/A
ROIC N/A
ROA(3y)-63.75%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SCLX Yearly ROA, ROE, ROICSCLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 100 -100 200

1.3 Margins

SCLX has a Gross Margin of 66.45%. This is in the better half of the industry: SCLX outperforms 70.27% of its industry peers.
SCLX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.45%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SCLX Yearly Profit, Operating, Gross MarginsSCLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

0

2. Health

2.1 Basic Checks

SCLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
SCLX has less shares outstanding than it did 1 year ago.
Compared to 1 year ago, SCLX has a worse debt to assets ratio.
SCLX Yearly Shares OutstandingSCLX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 50M 100M
SCLX Yearly Total Debt VS Total AssetsSCLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

SCLX has an Altman-Z score of -11.98. This is a bad value and indicates that SCLX is not financially healthy and even has some risk of bankruptcy.
SCLX has a Altman-Z score of -11.98. This is in the lower half of the industry: SCLX underperforms 77.84% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -11.98
ROIC/WACCN/A
WACC9.1%
SCLX Yearly LT Debt VS Equity VS FCFSCLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 100M -100M

2.3 Liquidity

SCLX has a Current Ratio of 0.19. This is a bad value and indicates that SCLX is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.19, SCLX is not doing good in the industry: 97.84% of the companies in the same industry are doing better.
SCLX has a Quick Ratio of 0.19. This is a bad value and indicates that SCLX is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.17, SCLX is not doing good in the industry: 97.30% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.19
Quick Ratio 0.17
SCLX Yearly Current Assets VS Current LiabilitesSCLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

SCLX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1838.18%.
SCLX shows a strong growth in Revenue. In the last year, the Revenue has grown by 292.17%.
EPS 1Y (TTM)-1838.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-74.16%
Revenue 1Y (TTM)292.17%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%12.95%

3.2 Future

SCLX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.47% yearly.
SCLX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 38.34% yearly.
EPS Next Y33.75%
EPS Next 2Y51.66%
EPS Next 3Y30.55%
EPS Next 5Y12.47%
Revenue Next Year27.26%
Revenue Next 2Y63.44%
Revenue Next 3Y66.67%
Revenue Next 5Y38.34%

3.3 Evolution

SCLX Yearly Revenue VS EstimatesSCLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
SCLX Yearly EPS VS EstimatesSCLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.2 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SCLX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SCLX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SCLX Price Earnings VS Forward Price EarningsSCLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCLX Per share dataSCLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

SCLX's earnings are expected to grow with 30.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y51.66%
EPS Next 3Y30.55%

More info and screens

0

5. Dividend

5.1 Amount

SCLX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCILEX HOLDING CO

NASDAQ:SCLX (2/21/2025, 8:00:01 PM)

After market: 0.3386 +0.01 (+2.67%)

0.3298

-0.01 (-1.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-17 2025-01-17/amc
Earnings (Next)N/A N/A
Inst Owners20.39%
Inst Owner Change-95.25%
Ins Owners0.38%
Ins Owner Change-1.13%
Market Cap80.24M
Analysts82
Price Target10.86 (3192.9%)
Short Float %2.41%
Short Ratio3.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-132.24%
Min EPS beat(2)-256.34%
Max EPS beat(2)-8.13%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.81%
Min Revenue beat(2)-19.06%
Max Revenue beat(2)15.44%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)36.32%
PT rev (3m)39.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)12.83%
EPS NY rev (3m)12.83%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-6.47%
Revenue NY rev (3m)-6.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.72
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.25
EYN/A
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS0.19
BVpS-0.71
TBVpS-0.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -164.82%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.45%
FCFM N/A
ROA(3y)-63.75%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.96%
Cap/Sales 0.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.19
Quick Ratio 0.17
Altman-Z -11.98
F-Score2
WACC9.1%
ROIC/WACCN/A
Cap/Depr(3y)20.05%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1838.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-74.16%
EPS Next Y33.75%
EPS Next 2Y51.66%
EPS Next 3Y30.55%
EPS Next 5Y12.47%
Revenue 1Y (TTM)292.17%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%12.95%
Revenue Next Year27.26%
Revenue Next 2Y63.44%
Revenue Next 3Y66.67%
Revenue Next 5Y38.34%
EBIT growth 1Y-375.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y9.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.59%
OCF growth 3YN/A
OCF growth 5YN/A